Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ISRCTN11121053) titled 'Effect of triiodothyronine (T3) in heart failure with reduced ejection (HFrEF)' on May 21.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Single
Purpose: Treatment, Safety
Primary Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust
Condition:
Heart failure with reduced ejection fraction and low serum T3 levels
Circulatory System
Intervention:
Intervention: 10 mcg oral liothyronine sodium capsule taken orally twice daily for 24 weeks.
Control: Matched placebo capsule, taken orally twice daily for 24 week...